Search results
From Nurse To Patient: My Journey With Crohn’s Disease
Women's Health via Yahoo News· 2 years agoAs a healthcare professional, Alison spent her days doing endoscopies, which are one of the many...
IBD Stock Of The Day Eli Lilly Breaks Out On Its Way To A Record High
Investor's Business Daily· 4 days agoEli Lilly is Tuesday's IBD Stock Of The Day after shares surged into a buy zone, again, on promising...
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript March 20, 2024 Rani...
The Unexpected Bad News For Novo's Ozempic In Biden's Drug Negotiations List
Investor's Business Daily· 9 months agoThere's a piece of bad news for Novo Nordisk's massively popular diabetes drug Ozempic in Medicare's...
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
Motley Fool· 1 year agoInvestors looking for reliable dividend stocks to buy will inevitably run into Johnson & Johnson...
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
Zacks via Yahoo Finance· 8 months agoThe FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo...
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Zacks via Yahoo Finance· 1 month agoThis week, J&J JNJ began the first-quarter 2024 earnings season for the pharma space with mixed...
10 Best Stocks to Buy According to Thomas Bailard’s Hedge Fund
Insider Monkey via Yahoo Finance· 2 years agoThis article discusses the top 10 stock picks of Thomas Bailard’s hedge fund Bailard Inc at the end...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters via Yahoo Finance· 2 weeks agoTeva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's...
Zacks Industry Outlook Highlights Johnson & Johnson, Novo Nordisk, Merck and AstraZeneca
Zacks via Yahoo Finance· 1 year agoFor Immediate Release Chicago, IL – December 15, 2022 – Today, Zacks Equity Research discusses...